Literature DB >> 24737678

TPMT and MTHFR genotype is not associated with altered risk of thioguanine-related sinusoidal obstruction syndrome in pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Lisa Wray1, Marijana Vujkovic, Thomas McWilliams, Shannon Cannon, Meenakshi Devidas, Linda Stork, Richard Aplenc.   

Abstract

Sinusoidal obstruction syndrome is a complication of therapy for pediatric ALL and may be modified by thiopurine methyltransferase activity as well as by MTHFR genotype. We assessed TPMT *3A, *3B, *3C, and MTHFR C677T and A1298C germline genetic polymorphisms among 351 patients enrolled in the thioguanine treatment arm of CCG-1952 clinical trial. TPMT and MTHFR C677T genotypes were not associated with SOS risk. The combination of MTHFR and TPMT variant genotypes was not associated with SOS risk. These suggest that germline genetic variation in TPMT and MTHFR do not significantly alter SOS risk in patients exposed to thioguanine.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  MTHFR; SOS; TPMT; acute lymphoblastic leukemia; thioguanine; toxicity

Mesh：

Substances：

Year:  2014        PMID： 24737678      PMCID： PMC4283196          DOI： 10.1002/pbc.25057

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  10 in total

1.  Genetic variation in the MTHFR gene influences thiopurine methyltransferase activity.

Authors:  Monica Arenas; Gemma Simpson; Cathryn M Lewis; El-Monsor Shobowale-Bakre; Emilia Escuredo; Lynette D Fairbanks; John A Duley; Azhar Ansari; Jeremy D Sanderson; Anthony M Marinaki
Journal:  Clin Chem       Date:  2005-12       Impact factor: 8.327

2.  The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.

Authors:  Lynne Lennard; Sue Richards; Cher S Cartwright; Chris Mitchell; John S Lilleyman; Ajay Vora
Journal:  Clin Pharmacol Ther       Date:  2006-10       Impact factor: 6.875

3.  Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).

Authors:  Shana S Jacobs; Linda C Stork; Bruce C Bostrom; Ray Hutchinson; John Holcenberg; Gregory H Reaman; Gary Erdmann; Janet Franklin; Joseph P Neglia; Seth M Steinberg; Frank M Balis; Peter C Adamson
Journal:  Pediatr Blood Cancer       Date:  2007-09       Impact factor: 3.167

4.  Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.

Authors:  Yousif Matloub; Susan Lindemulder; Paul S Gaynon; Harland Sather; Mei La; Emmett Broxson; Rochelle Yanofsky; Raymond Hutchinson; Nyla A Heerema; James Nachman; Marilyn Blake; Linda M Wells; April D Sorrell; Margaret Masterson; John F Kelleher; Linda C Stork
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

5.  Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.

Authors:  Linda C Stork; Yousif Matloub; Emmett Broxson; Mei La; Rochelle Yanofsky; Harland Sather; Ray Hutchinson; Nyla A Heerema; April D Sorrell; Margaret Masterson; Archie Bleyer; Paul S Gaynon
Journal:  Blood       Date:  2010-02-01       Impact factor: 22.113

6.  Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia.

Authors:  Sara Stoneham; Lynne Lennard; Pietro Coen; John Lilleyman; Vaskar Saha
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

Review 7.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Authors:  Jason A Coppell; Paul G Richardson; Robert Soiffer; Paul L Martin; Nancy A Kernan; Allen Chen; Eva Guinan; Georgia Vogelsang; Amrita Krishnan; Sergio Giralt; Carolyn Revta; Nicole A Carreau; Massimo Iacobelli; Enric Carreras; Tapani Ruutu; Tiziano Barbui; Joseph H Antin; Dietger Niederwieser
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-18       Impact factor: 5.742

8.  Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?

Authors:  M Fakhoury; J Andreu-Gallien; A Mahr; Y Medard; S Azougagh; E Vilmer; E Jacqz-Aigrain
Journal:  J Clin Pharm Ther       Date:  2007-12       Impact factor: 2.512

9.  Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation.

Authors:  Eray Goekkurt; Jan Stoehlmacher; Christian Stueber; Christine Wolschke; Thomas Eiermann; Simona Iacobelli; Axel R Zander; Gerhard Ehninger; Nicolaus Kröger
Journal:  Anticancer Res       Date:  2007 Nov-Dec       Impact factor: 2.480

10.  Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia.

Authors:  V Rocha; R Porcher; J F Fernandes; A Filion; H Bittencourt; W Silva; G Vilela; D L Zanette; C Ferry; J Larghero; A Devergie; P Ribaud; Y Skvortsova; R Tamouza; E Gluckman; G Socie; M A Zago
Journal:  Leukemia       Date:  2008-11-13       Impact factor: 11.528
  10 in total
  4 in total

Review 1.  Genetic Predictors for Sinusoidal Obstruction Syndrome-A Systematic Review.

Authors:  Nicolas Waespe; Sven Strebel; Simona Jurkovic Mlakar; Maja Krajinovic; Claudia Elisabeth Kuehni; Tiago Nava; Marc Ansari
Journal:  J Pers Med       Date:  2021-04-26

2.  Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review.

Authors:  Linea Natalie Toksvang; Magnus Strøh Schmidt; Sofie Arup; Rikke Hebo Larsen; Thomas Leth Frandsen; Kjeld Schmiegelow; Cecilie Utke Rank
Journal:  PLoS One       Date:  2019-05-24       Impact factor: 3.240

3.  Severe Hepatic Sinusoidal Obstruction Syndrome in a Child Receiving Vincristine, Actinomycin-D, and Cyclophosphamide for Rhabdomyosarcoma: Successful Treatment with Defibrotide.

Authors:  Aery Choi; Young Kyung Kang; Sewon Lim; Dong Ho Kim; Jung Sub Lim; Jun Ah Lee
Journal:  Cancer Res Treat       Date:  2016-03-30       Impact factor: 4.679

4.  Associations between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG-1952.

Authors:  Marijana Vujkovic; Aaron Kershenbaum; Lisa Wray; Thomas McWilliams; Shannon Cannon; Meenakshi Devidas; Linda Stork; Richard Aplenc
Journal:  Leuk Res Rep       Date:  2015-07-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.